Engineering the redox potential over a wide range within a new class of FeS proteins

John A. Zuris, Danny A. Halim, Andrea R. Conlan, Edward C. Abresch, Rachel Nechushtai, Mark L. Paddock, Patricia A. Jennings

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


MitoNEET is a newly discovered mitochondrial protein and a target of the TZD class of antidiabetes drugs. MitoNEET is homodimeric with each protomer binding a [2Fe-2S] center through a rare 3-Cys and 1-His coordination geometry. Both the fold and the coordination of the [2Fe-2S] centers suggest that it could have novel properties compared to other known [2Fe-2S] proteins. We tested the robustness of mitoNEET to mutation and the range over which the redox potential (EM) could be tuned. We found that the protein could tolerate an array of mutations that modified the EM of the [2Fe-2S] center over a range of ∼700 mV, which is the largest EM range engineered in an FeS protein and, importantly, spans the cellular redox range (+200 to-300 mV). These properties make mitoNEET potentially useful for both physiological studies and industrial applications as a stable, water-soluble, redox agent.

Original languageAmerican English
Pages (from-to)13120-13122
Number of pages3
JournalJournal of the American Chemical Society
Issue number38
StatePublished - 29 Sep 2010


Dive into the research topics of 'Engineering the redox potential over a wide range within a new class of FeS proteins'. Together they form a unique fingerprint.

Cite this